Nursing care
Misoprostol in Obstetrics: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Misoprostol is a prostaglandin E1 analogue used in obstetrics for cervical ripening before induction and for postpartum haemorrhage when uterotonics are needed. It is contraindicated in a patient with a previous Caesarean section because of the risk of uterine rupture. Assess contractions, fetal heart rate, and scar history before every dose.
Mechanism, simply
Misoprostol is a synthetic prostaglandin E1 analogue. It binds prostaglandin receptors in the myometrium and cervix, softening and effacing the cervix while stimulating uterine smooth muscle to contract.
That dual action is exactly what makes it useful in two very different obstetric moments: ripening a cervix that is not yet ready for labour, and contracting a uterus that will not stop bleeding after delivery. The same mechanism that opens the cervix before birth is the mechanism that clamps the uterus down afterward, which is why the drug appears at both ends of the birth process.
Indications you will see on the ward
On an antenatal or labour ward, misoprostol is most often given vaginally, orally, or buccally to ripen an unfavourable cervix ahead of induction of labour, particularly for post-term pregnancy, preeclampsia requiring delivery, or intrauterine fetal demise.
On a postpartum unit, it is given, often rectally or sublingually, as a second- or third-line uterotonic for postpartum haemorrhage when oxytocin alone has not controlled bleeding. It is also used in early pregnancy loss management and in some settings for medical termination in combination with mifepristone.
Assessment before administration
Confirm obstetric history before every induction dose, specifically any previous Caesarean section or major uterine surgery. Misoprostol is contraindicated in this population because the drug's contractile force against a scarred uterine wall carries a meaningfully higher risk of uterine rupture than oxytocin-based induction.
Establish a baseline fetal heart rate tracing and maternal vital signs, and confirm the uterus is being monitored continuously once the drug is given. Check the current contraction pattern, since misoprostol should not be given on top of an already contracting or hyperstimulated uterus. Review allergy history and confirm the ordered route and dose match the indication, since induction and haemorrhage dosing differ substantially.
Toxicity and the antidote
There is no specific antidote for misoprostol. Toxicity in obstetric use presents as uterine tachysystole, more than five contractions in ten minutes, often with a non-reassuring fetal heart rate pattern such as late decelerations or a rising baseline.
Management is supportive: stop any further doses, reposition the patient in a lateral position, start or increase intravenous fluids, apply supplemental oxygen, and notify the provider immediately. A tocolytic such as terbutaline may be ordered to relax the uterus if hyperstimulation persists. Continuous fetal monitoring stays in place until the pattern resolves.
Interactions that matter
The interaction that matters most clinically is not pharmacokinetic, it is sequential: misoprostol should not be administered close together with oxytocin, and most protocols require a defined interval, commonly around four hours, between the last misoprostol dose and starting an oxytocin infusion, to avoid stacking uterotonic effect and precipitating tachysystole.
Other prostaglandins, such as dinoprostone, are not given concurrently for the same reason. Nonsteroidal anti-inflammatory drugs can theoretically blunt prostaglandin effect and are generally avoided during active induction. There is no significant food interaction, but antacids can reduce oral absorption slightly, which is one reason buccal, vaginal, or sublingual routes are often preferred in obstetric protocols.
What the patient must be told
Explain that cramping and some vaginal spotting are expected after a ripening dose, but that contractions coming faster than every two minutes, severe or constant pain, heavy bleeding, or a marked change in fetal movement need to be reported immediately, not saved for the next round.
For a patient receiving misoprostol for postpartum haemorrhage, explain that shivering, diarrhoea, and a transient fever are common side effects and are not a sign the treatment has failed. Confirm with every patient before the first dose whether they have had a prior Caesarean section or uterine surgery, since this history determines whether the drug can be used at all, and document that confirmation clearly in the chart.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our maternity and newborn practice questions are the closest set to what this page covers.
Common questions
Why is misoprostol contraindicated after a previous Caesarean section?
The uterine scar from a prior Caesarean is a point of structural weakness, and misoprostol's contractile effect on the myometrium raises the risk of uterine rupture at that scar. This risk is higher with misoprostol than with oxytocin, so oxytocin or mechanical methods are preferred for induction in this population.
What route is misoprostol given by for postpartum haemorrhage?
Rectal and sublingual routes are the most common for postpartum haemorrhage, though this varies by protocol and facility. The dose and route for haemorrhage control differ from those used for cervical ripening, so confirm the indication before administering.
How soon after misoprostol can oxytocin be started?
Most protocols require a defined interval, often around four hours, after the last misoprostol dose before starting an oxytocin infusion. This spacing reduces the risk of stacking uterotonic effects and causing uterine tachysystole.
What is uterine tachysystole and how is it managed?
Tachysystole is more than five contractions in a ten-minute window, often with fetal heart rate changes. Management includes stopping further misoprostol, repositioning the patient, giving oxygen and intravenous fluids, and notifying the provider, with a tocolytic considered if it does not resolve.